<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.03.23.21253520</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Infectious Diseases (except HIV/AIDS)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Optimizing SARS-CoV-2 Variant of Concern Screening: Experience from British Columbia, Canada, Early 2021</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1977-253X</contrib-id>
<name><surname>Hogan</surname><given-names>Catherine A.</given-names></name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sbihi</surname><given-names>Hind</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jassem</surname><given-names>Agatha</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Prystajecky</surname><given-names>Natalie</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tyson</surname><given-names>John R.</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Tracy D.</given-names></name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tsang</surname><given-names>Frankie</given-names></name>
<degrees>BMLSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ng</surname><given-names>Corrinne</given-names></name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Janz</surname><given-names>Loretta</given-names></name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Romney</surname><given-names>Marc G.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7769-6120</contrib-id>
<name><surname>Hoang</surname><given-names>Linda</given-names></name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<aff id="a1"><label>1</label><institution>British Columbia Centre for Disease Control Public Health Laboratory</institution>, Vancouver, British Columbia, <country>Canada</country></aff>
<aff id="a2"><label>2</label><institution>School of Population and Public Health, University of British Columbia</institution>, Vancouver, British Columbia, <country>Canada</country></aff>
<aff id="a3"><label>3</label><institution>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver</institution>, British Columbia, <country>Canada</country></aff>
<aff id="a4"><label>4</label><institution>Division of Medical Microbiology and Virology, St. Paul&#x2019;s Hospital, Vancouver</institution>, British Columbia, <country>Canada</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Address for correspondence: Catherine A. Hogan, British Columbia Centre for Disease Control 655 W 12<sup>th</sup> Ave, Room 2054, Vancouver, British Columbia, Canada Email: <email>catherine.hogan@bccdc.ca</email>; Phone (604) 707-5667</corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.03.23.21253520</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>3</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>3</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>3</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license><license-p>The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</license-p></license>
</permissions>
<self-uri xlink:href="21253520.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Comprehensive and timely testing is required for SARS-CoV-2 variant of concern (VoC) screening. Whole genome sequencing (WGS) provides the broadest means to detect circulating VoCs, but requires longer turnaround time than targeted molecular testing by quantitative polymerase chain reaction (qPCR). We demonstrated the feasibility of a combined testing approach for VoC prevalence assessment in British Columbia, and showed high concordance between qPCR testing and WGS. This directly informed wider VoC screening strategy implementation, and public health efforts.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>SARS-CoV-2</kwd>
<kwd>variant of concern</kwd>
<kwd>testing</kwd>
<kwd>public health</kwd>
<kwd>COVID-19</kwd>
</kwd-group>
<counts>
<page-count count="18"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>No funding.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>As per TCPS2 2018 Article 2.5 https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter2-chapitre2.html#5:
Quality assurance and quality improvement studies, program evaluation activities, and performance reviews, or testing within normal educational requirements when used exclusively for assessment, management or improvement purposes, do not constitute research for the purposes of this Policy, and do not fall within the scope of REB review.
Application
Article 2.5 refers to assessments of the performance of an organization or its employees or students, within the mandate of the organization, or according to the terms and conditions of employment or training. Those activities are normally administered in the ordinary course of the operation of an organization where participation is required, for example, as a condition of employment in the case of staff performance reviews, or an evaluation in the course of academic or professional training. Other examples include student course evaluations, or data collection for internal or external organizational reports. Such activities do not normally follow the consent procedures outlined in this Policy.
If data are collected for the purposes of such activities but later proposed for research purposes, it would be considered secondary use of information not originally intended for research, and at that time may require REB review in accordance with this Policy. Refer to Section D of Chapter 5 for guidance concerning secondary use of identifiable information for research purposes.
We confirm that this work submitted does not require REB review or approval. Thanks.
Pia Ganz
Manager, Clinical Research Ethics
Office of Research Ethics
VP Research and Innovation
The University of British Columbia
Room 210, 828 West 10th Ave
Vancouver Hospital Research Pavilion
Vancouver BC V5Z 1L8</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Identification of mutations in the SARS-CoV-2 genome has led to the recognition of variants of concern (VoCs) based on their association with increased transmissibility, clinical severity, and/or reduced vaccine efficacy (<xref ref-type="bibr" rid="c1">1</xref>-<xref ref-type="bibr" rid="c5">5</xref>). Globally, lineages B.1.1.7, B.1.351, and P.1 represent the three currently circulating VoCs (<xref ref-type="bibr" rid="c6">6</xref>). Whole genome sequencing (WGS) provides the most comprehensive means to detect circulating VoCs, but requires considerable resources and time to perform. VoC screening workflows using quantitative polymerase chain reaction (qPCR) optimize testing capacity and turnaround time to enable appropriate and timely public health interventions (<xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c8">8</xref>).</p>
</sec>
<sec id="s2">
<title>Methods</title>
<p>The British Columbia Centre for Disease Control Public Health Laboratory (BCCDC PHL) serves as the reference laboratory for the province. A combined VoC testing strategy based on direct WGS and targeted N501Y mutation qPCR was employed to estimate point prevalence (<bold><xref rid="figA1" ref-type="fig">Appendix Figure 1</xref></bold>) based on samples resulted as positive for SARS-CoV-2 from January 30<sup>th</sup> to February 5<sup>th</sup> 2021. Specimens not tested directly by WGS were screened by an assay targeting the envelope (<italic>E</italic>) gene and N501Y mutation, which detects but does not differentiate the three main VoCs, in two laboratories (<bold>Supplementary methods</bold>). Specimens with a detected N501Y mutation underwent confirmatory testing and typing by WGS (<bold>Supplementary methods</bold>).</p>
<p>Ongoing surveillance was continued from February 6<sup>th</sup> to March 6<sup>th</sup> 2021 to monitor evolution in VoC prevalence. Epidemiologic and laboratory data collection was performed based on linkage of provincial databases. This work was conducted under the public health mandate and institutional review board approval was waived.</p>
</sec>
<sec id="s3">
<title>Results</title>
<p>A total of 3,024 specimens underwent either direct WGS or screening by N501Y assay, representing over 97&#x0025; of the 3,101 SARS-CoV-2-positive samples in British Columbia for the sampling period (<bold><xref rid="fig1" ref-type="fig">Figure 1</xref></bold>). The prevalence of VoCs by both pathways, direct WGS and N501Y qPCR screening, was below 1&#x0025;. Of the 27 individuals with a confirmed VoC, the median age was 28 years (interquartile range, 20-40), and 11 were female. A total of 23 B.1.1.7 and 4 B.1.351 lineages were confirmed, and there was no P.1 lineage identified during this period (<bold><xref rid="tbl1" ref-type="table">Table 1</xref></bold>). Geographical stratification revealed confirmed cases were concentrated in two health authorities (<bold><xref rid="figA2" ref-type="fig">Appendix Figure 2</xref>)</bold>. Furthermore, direct WGS enabled the identification of one case of B.1.525 lineage (<bold><xref rid="figA2" ref-type="fig">Appendix Figure 2</xref></bold>), which pointed to the recent emergence of a lineage of Nigerian origin in Canada during this time period (<xref ref-type="bibr" rid="c9">9</xref>). Continued surveillance by N501Y screening revealed a progressive increase in VoC prevalence in British Columbia, reaching over 10&#x0025; by the end of February 2021 (<bold><xref rid="tblA1" ref-type="table">Appendix Table 1</xref></bold>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><p>Flowchart of the screening and direct WGS testing results. The prevalence of SARS-CoV-2 variants of concern was &#x003C;1&#x0025; in both pathways. Most specimens were identified as B.1.1.7 lineage, and there was no P.1 lineage identified. One specimen underwent WGS twice but generated only an incomplete genome; for prevalence analysis, this specimen was considered as a confirmed VoC.</p>
<p>BC: British Columbia; BCCDC: British Columbia Centre for Disease Control; CI: confidence interval; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SPH: St Paul&#x2019;s Hospital; VoC: variant of concern; WGS: whole genome sequencing.</p></caption>
<graphic xlink:href="21253520v1_fig1.tif"/>
</fig>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>Epidemiologic and laboratory characteristics of the 28 individuals with presumptive or confirmed SARS-CoV-2 variants of concern identified in the study.</p></caption>
<graphic xlink:href="21253520v1_tbl1.tif"/>
<graphic xlink:href="21253520v1_tbl1a.tif"/>
</table-wrap>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>Results from this point prevalence study of over 3,000 specimens demonstrated the feasibility of a province-wide combined VoC screening strategy incorporating WGS and N501Y qPCR screening, and showed low prevalence of VoCs with predominance of B.1.1.7 lineage in British Columbia in early 2021. This assessment provided the critical prevalence data required to benchmark VoC burden, and to inform planning of an optimized VoC detection strategy moving forward.</p>
<p>The BCCDC PHL currently performs the highest proportion of WGS in Canada, with up to 25&#x0025; of SARS-CoV-2-positive specimens sequenced. However, this high-complexity approach necessitates specialized equipment and expertise, and computationally-intensive analysis that prolongs result turnaround time. Thus, even in specialized centralized settings, VoC testing alternatives are needed. In this study, given that most cases identified by N501Y screen were confirmed as VoCs, increasing the proportion of PCR-based screening over WGS upfront was deemed appropriate. Based on these data, the N501Y screening strategy was expanded to clinical laboratories across the province to decentralize testing, increase testing capacity, and reduce turnaround time to presumptive VoC identification. Subsequent point prevalence assessments based on this decentralized model are now planned for ongoing surveillance. However, a limitation of this approach is that emergence of variants devoid of N501Y mutation such as the recently-recognized B.1.525, reported here, may be underestimated due to failure of detection by qPCR targets employed, and requires alternative qPCR assays for identification (<xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c10">10</xref>).</p>
<p>In summary, this study demonstrated the feasibility of a combined targeted and WGS testing strategy for VoC prevalence assessment in one Canadian province, which will be instrumental for continued VoC surveillance, and to inform public health efforts.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>Data are available from the corresponding author upon reasonable request.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We thank the molecular, virology, bacteriology staff and microbiologists of the BCCDC Public Health Laboratory for their contribution toward testing, without which this work would not have been possible. We thank Rebecca Hickman, BSc and Ji-In Hum, BSc for their contributions toward test procedure development and result interpretation. We thank Chris Fjell, PhD, Braeden Klaver, MPH and Yayuk Joffres, MPH, and the BCCDC data analytics team for implementing the data collection and entry systems that enabled this work. We thank Drs. Nancy Matic, MD and Christopher Lowe, MD and the virology laboratory staff from St. Paul&#x2019;s Hospital for sharing and verifying VoC data. We also thank the British Columbia Association of Medical Microbiologists for sharing samples and data that enabled province-wide data collection, and testing.</p>
</ack>
<sec id="s5">
<title>Funding</title>
<p>None</p>
</sec>
<sec id="s6">
<title>Disclosure</title>
<p>None</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="other"><string-name><surname>Walensky</surname> <given-names>RP</given-names></string-name>, <string-name><surname>Walke</surname> <given-names>HT</given-names></string-name>, <string-name><surname>Fauci</surname> <given-names>AS</given-names></string-name>. <year>2021</year>. <article-title>SARS-CoV-2 Variants of Concern in the United States&#x2014;Challenges and Opportunities</article-title>. <source>JAMA</source> doi:<pub-id pub-id-type="doi">10.1001/jama.2021.2294</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Galloway</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Paul</surname> <given-names>P</given-names></string-name>, <string-name><surname>MacCannell</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Johansson</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Brooks</surname> <given-names>JT</given-names></string-name>, <string-name><surname>MacNeil</surname> <given-names>A</given-names></string-name>, <string-name><surname>Slayton</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Tong</surname> <given-names>S</given-names></string-name>, <string-name><surname>Silk</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Armstrong</surname> <given-names>GL</given-names></string-name>, <string-name><surname>Biggerstaff</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dugan</surname> <given-names>VG</given-names></string-name>. <year>2021</year>. <article-title>Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States</article-title>, <month>December</month> 29, 2020-January 12, 2021. <source>MMWR Morb Mortal Wkly Rep</source> <volume>70</volume>:<fpage>95</fpage>&#x2013;<lpage>99</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Muik</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wallisch</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Sanger</surname> <given-names>B</given-names></string-name>, <string-name><surname>Swanson</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Muhl</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>W</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>H</given-names></string-name>, <string-name><surname>Maurus</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sarkar</surname> <given-names>R</given-names></string-name>, <string-name><surname>Tureci</surname> <given-names>O</given-names></string-name>, <string-name><surname>Dormitzer</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Sahin</surname> <given-names>U.</given-names></string-name> <year>2021</year>. <article-title>Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera</article-title>. <source>Science</source> <volume>371</volume>:<fpage>1152</fpage>&#x2013;<lpage>1153</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="other"><string-name><surname>Davies</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Abbott</surname> <given-names>S</given-names></string-name>, <string-name><surname>Barnard</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Jarvis</surname> <given-names>CI</given-names></string-name>, <string-name><surname>Kucharski</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Munday</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Pearson</surname> <given-names>CAB</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>TW</given-names></string-name>, <string-name><surname>Tully</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Washburne</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Wenseleers</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gimma</surname> <given-names>A</given-names></string-name>, <string-name><surname>Waites</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>KLM</given-names></string-name>, <string-name><surname>van Zandvoort</surname> <given-names>K</given-names></string-name>, <string-name><surname>Silverman</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Group</surname> <given-names>CC-W</given-names></string-name>, <string-name><surname>Consortium</surname> <given-names>C-GU</given-names></string-name>, <string-name><surname>Diaz-Ordaz</surname> <given-names>K</given-names></string-name>, <string-name><surname>Keogh</surname> <given-names>R</given-names></string-name>, <string-name><surname>Eggo</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Funk</surname> <given-names>S</given-names></string-name>, <string-name><surname>Jit</surname> <given-names>M</given-names></string-name>, <string-name><surname>Atkins</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Edmunds</surname> <given-names>WJ</given-names></string-name>. <year>2021</year>. <article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England</article-title>. <source>Science</source> doi:<pub-id pub-id-type="doi">10.1126/science.abg3055</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="book"><string-name><surname>Challen</surname> <given-names>R</given-names></string-name>, <string-name><surname>Brooks-Pollock</surname> <given-names>E</given-names></string-name>, <string-name><surname>Read</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Dyson</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tsaneva-Atanasova</surname> <given-names>K</given-names></string-name>, <string-name><surname>Danon</surname> <given-names>L.</given-names></string-name> <year>2021</year>. <chapter-title>Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study</chapter-title>. <source>BMJ</source> <volume>372</volume>:<publisher-name>579</publisher-name>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="website"><collab>GISAID</collab>. <year>2021</year>. <source>Tracking of Variants</source>. <ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/hcov19-variants/">https://www.gisaid.org/hcov19-variants/</ext-link>. Accessed <date-in-citation content-type="access-date">February 20 2021</date-in-citation>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="website"><collab>ECCDC</collab>. <year>2021</year>. <source>Sequencing of SARS-CoV-2: first update</source>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="website"><collab>ECCDC</collab>. <year>2021</year>. <source>Methods for the detection and identification of SARS-CoV-2 variants</source>. <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants.pdf</ext-link>. Accessed <date-in-citation content-type="access-date">March 13 2021</date-in-citation>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="website"><collab>GISAID</collab>. <year>2021</year>. <source>B.1.525 2021-02-20</source>. <ext-link ext-link-type="uri" xlink:href="https://cov-lineages.org/global_report_B.1.525.html">https://cov-lineages.org/global_report_B.1.525.html</ext-link>. Accessed <date-in-citation content-type="access-date">March 12 2021</date-in-citation>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Bal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Destras</surname> <given-names>G</given-names></string-name>, <string-name><surname>Gaymard</surname> <given-names>A</given-names></string-name>, <string-name><surname>Stefic</surname> <given-names>K</given-names></string-name>, <string-name><surname>Marlet</surname> <given-names>J</given-names></string-name>, <string-name><surname>Eymieux</surname> <given-names>S</given-names></string-name>, <string-name><surname>Regue</surname> <given-names>H</given-names></string-name>, <string-name><surname>Semanas</surname> <given-names>Q</given-names></string-name>, <string-name><surname>d&#x2019;Aubarede</surname> <given-names>C</given-names></string-name>, <string-name><surname>Billaud</surname> <given-names>G</given-names></string-name>, <string-name><surname>Laurent</surname> <given-names>F</given-names></string-name>, <string-name><surname>Gonzalez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mekki</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Valette</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bouscambert</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gaudy-Graffin</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lina</surname> <given-names>B</given-names></string-name>, <string-name><surname>Morfin</surname> <given-names>F</given-names></string-name>, <string-name><surname>Josset</surname> <given-names>L</given-names></string-name>, <string-name><given-names>Group</given-names> <surname>CO-DHS</surname></string-name>. <year>2021</year>. <article-title>Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020</article-title>. <source>Euro Surveill</source> <volume>26</volume>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Corman</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Landt</surname> <given-names>O</given-names></string-name>, <string-name><surname>Kaiser</surname> <given-names>M</given-names></string-name>, <string-name><surname>Molenkamp</surname> <given-names>R</given-names></string-name>, <string-name><surname>Meijer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Chu</surname> <given-names>DKW</given-names></string-name>, <string-name><surname>Bleicker</surname> <given-names>T</given-names></string-name>, <string-name><surname>Brunink</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schneider</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schmidt</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Mulders</surname> <given-names>D</given-names></string-name>, <string-name><surname>Haagmans</surname> <given-names>BL</given-names></string-name>, <string-name><surname>van der Veer</surname> <given-names>B</given-names></string-name>, <string-name><surname>van den Brink</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wijsman</surname> <given-names>L</given-names></string-name>, <string-name><surname>Goderski</surname> <given-names>G</given-names></string-name>, <string-name><surname>Romette</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Ellis</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zambon</surname> <given-names>M</given-names></string-name>, <string-name><surname>Peiris</surname> <given-names>M</given-names></string-name>, <string-name><surname>Goossens</surname> <given-names>H</given-names></string-name>, <string-name><surname>Reusken</surname> <given-names>C</given-names></string-name>, <string-name><surname>Koopmans</surname> <given-names>MPG</given-names></string-name>, <string-name><surname>Drosten</surname> <given-names>C.</given-names></string-name> <year>2020</year>. <article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>. <source>Euro Surveill</source> <volume>25</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Freed</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Vlkova</surname> <given-names>M</given-names></string-name>, <string-name><surname>Faisal</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Silander</surname> <given-names>OK</given-names></string-name>. <year>2020</year>. <article-title>Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding</article-title>. <source>Biol Methods Protoc</source> <volume>5</volume>:<fpage>bpaa014</fpage>.</mixed-citation></ref>
</ref-list>
<sec id="s7">
<title>Supplementary methods</title>
<sec id="s7a">
<title>N501Y mutation screening</title>
<sec id="s7a1">
<title>BCCDC</title>
<p>The British Columbia Centre for Disease Control (BCCDC) public health laboratory developed a real-time, duplex reverse transcription polymerase chain reaction assay targeting the envelope (<italic>E</italic>) gene and the N501Y mutation (A23063T) of the Spike (S) protein. The <italic>E</italic> gene probe was used to confirm detection of SARS-CoV-2 RNA in the specimen, as previously described by Corman <italic>et al</italic>.(<xref ref-type="bibr" rid="c11">11</xref>) The N501Y mutation is detected in the three main currently circulating Variants of Concern (VoCs): lineage B.1.1.7 (variant first described in the UK), B.1.351 (variant first described in South Africa), and lineage P.1 (variant described in Brazil). Briefly, total nucleic acids were extracted from 200&#x03BC;L of upper respiratory specimen matrix (universal transport medium or saline) using the Applied BioSystems MagMax&#x2122; Express 96 Nucleic Acid Extractor and the MagMax Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer&#x2019;s recommendations. Real-time RT-PCR was performed using the TaqMan Fast Virus Master Mix (Thermo Fisher Scientific) on the Applied Biosystems 7500 FAST real-time PCR system (Thermo Fisher Scientific). PCR set-up was performed using a volume of 5&#x00B5;L of patient specimen extract, for a final reaction volume of 20&#x00B5;L.</p>
</sec>
<sec id="s7a2">
<title>St. Paul&#x2019;s Hospital</title>
<p>The St. Paul&#x2019;s Hospital Clinical Microbiology Laboratory developed a real-time, reverse transcription polymerase chain reaction assay targeting the <italic>E</italic> gene and the N501Y mutation (A23063T) of the Spike (S) protein. Following extraction of viral RNA, SARS-CoV-2 detection was performed using the LightMix&#x00AE; ModularDx SARS-CoV (COVID19) E-gene assay (TIB Molbiol, Berlin, Germany), or with the combined extraction and amplification automated cobas&#x00AE; SARS-CoV-2 Test (Roche Molecular Diagnostics, Laval, QC) using the cobas&#x00AE; 6800 instrument. A smaller number of clinical samples were tested using Xpert&#x00AE; Xpress SARS-CoV-2/Flu/RSV (Cepheid, Sunnyvale, CA). Positives for SARS-CoV-2 were re-extracted and then screened for N501Y Spike (S) protein mutation with the VirSNiP SARS-CoV-2 Mutation Assays for Strain Surveillance (TIB Molbiol) using Roche LightCycler 480&#x00AE; (Roche Molecular Diagnostics, Laval, QC). For the PCR reaction, 5 &#x00B5;L of extracted sample were added to the reaction mixture as per the manufacturer&#x2019;s instructions, and results were interpreted based on an analysis of amplification and melting curves.</p>
</sec>
<sec id="s7a3">
<title>BCCDC WGS testing</title>
<p>Whole genome sequencing was performed at the BCCDC PHL. In brief, SARS-CoV-2 RNA was extracted using the Applied BioSystems MagMax&#x2122; Express 96 Nucleic Acid Extractor and the MagMax Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher). Viral RNA was reverse transcribed into cDNA using Thermo SuperScript IV, and a two pool multiplex PCR with primers tiled across the entire SARS-CoV-2 genome, in 29 &#x223C;1200bp segments, was performed.(<xref ref-type="bibr" rid="c12">12</xref>) DNA libraries for whole genome sequencing on a MiSeq instrument (Illumina, San Diego) were prepared using DNA Prep Library Preparation Kit (Illumina). SARS-CoV-2 whole genome consensus sequences and mutation compositions were generated using a modified Nextflow pipeline for running the ARTIC network&#x2019;s (<ext-link ext-link-type="uri" xlink:href="https://artic.network/ncov-2019">https://artic.network/ncov-2019</ext-link>) fieldbioinformatics tools (<ext-link ext-link-type="uri" xlink:href="https://github.com/BCCDC-PHL/ncov2019-artic-nf">https://github.com/BCCDC-PHL/ncov2019-artic-nf</ext-link>). Reports detailing SARS-CoV-2 lineage information, sequencing QC metrics and mutational profiles were generated using ncov-tools from the Simpson Lab (<ext-link ext-link-type="uri" xlink:href="https://github.com/jts/ncov-tools">https://github.com/jts/ncov-tools</ext-link>).</p>
</sec>
<sec id="s7a4">
<title>Statistical analysis</title>
<p>Exact 95&#x0025; confidence intervals for proportions were calculated using Stata v.15.1 (Stata Corp, College Station, TX).</p>
</sec>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="Sc1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Corman</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Landt</surname> <given-names>O</given-names></string-name>, <string-name><surname>Kaiser</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>. <source>Euro Surveill</source>.<year>2020</year>;<volume>25</volume>(<issue>3</issue>):<fpage>1</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="Sc2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Freed</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Vlkova</surname> <given-names>M</given-names></string-name>, <string-name><surname>Faisal</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Silander</surname> <given-names>OK</given-names></string-name>. <article-title>Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding</article-title>. <source>Biol Methods Protoc</source>.<year>2020</year>;<volume>5</volume>(<issue>1</issue>):<fpage>bpaa014</fpage>.</mixed-citation></ref>
</ref-list>
<sec>
<table-wrap id="tblA1" orientation="portrait" position="float">
<label>Appendix Table 1.</label>
<caption><p>Variant of concern N501Y screening post-point prevalence study period, British Columbia, Canada, February-March 2021</p></caption>
<graphic xlink:href="21253520v1_tblA1.tif"/>
</table-wrap>
<fig id="figA1" position="float" fig-type="figure">
<label>Appendix Figure 1.</label>
<caption><p>Comparative analytical workflow of real-time reverse transcription polymerase chain reaction testing for N501Y mutation detection (left) vs whole genome sequencing (WGS) (right). The WGS process is significantly more complex, requires additional expertise and longer turnaround time than conventional PCR. A VoC detection strategy that leverages the uses of both approaches is needed to optimize laboratory testing capacity and turnaround time. (Figure created with BioRender)</p>
<p>RNA: ribonucleic acid; rRT-PCR: real-time reverse transcription polymerase chain reaction; WGS: whole genome sequencing.</p></caption>
<graphic xlink:href="21253520v1_figA1.tif"/>
</fig>
<fig id="figA2" position="float" fig-type="figure">
<label>Appendix Figure 2.</label>
<caption><p>Number of confirmed variants of concern (VoCs) in British Columbia, from January 30<sup>th</sup> to February 5<sup>th</sup> 2021 by resulting date. Geographical stratification of the data revealed that the confirmed VOC cases were concentrated in two health authorities, enabling focused public health efforts. Lineage B.1.1.7 strongly predominated, there was a single B.1.525 case, and there was no lineage P.1 identified during this time period.</p>
<p>BC: British Columbia; HA: health authority; Feb: February; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; WGS: whole genome sequencing.</p></caption>
<graphic xlink:href="21253520v1_figA2.tif"/>
</fig>
</sec>
</back>
</article>